Apollon Formularies Plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange is pleased to announce that its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing. ¹ This finding is in addition to the results recently announced on May 18, 2021² that Apollon formulations were successful in killing HER2+ breast cancer cells, and the announcement on June 28, 2021³ that Apollon formulations were successful in killing triple-negative breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ),a BC based international pharmaceutical company trading on the Canadian Securities Exchange.
Apollon Formularies (AQSE:APOL) | RNS | Apollon Formularies - Apollon Formulations Kill Prostate Cancer Cells
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma s Drug Compound pelcitoclax
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.